麻豆果冻传媒

For Release: July 22, 2010

MENLO PARK, Calif.聽- SRI International and the Stanford University School of Medicine announced today their MISTRAL Collaborative (the Multidisciplinary Initiative for Surgical Technology Research Advanced Laboratory), in conjunction with the Institute for Pediatric Innovation, was recently awarded a $1M grant by the Food and Drug Administration (FDA) to support its work to commercialize innovative medical devices for pediatric care.

A key objective for the FDA-funded project will be to identify opportunities for new medical devices specific to the聽newborn intensive care unit聽(NICU) setting. Other focus areas for pediatric product development will include surgical tools and catheter-related products. 鈥淐hildren are the 鈥榦rphans鈥� of the medical device industry,鈥� said聽Sanjeev Dutta, M.D., associate professor of surgery and of pediatrics at the Stanford University School of Medicine and attending surgeon at Lucile Packard Children鈥檚 Hospital at Stanford. 鈥淢arket and regulatory concerns often prevent medical device companies from investing in pediatric-specific device development. Not infrequently, appropriate devices that specifically address pediatric diseases are simply not available, leaving some practitioners to use adult devices on kids or 鈥榡erry-rig鈥� their own solutions. The MISTRAL Collaborative, with this tremendous boost from the FDA, hopes to catalyze pediatric device development by performing the initial R&D, partnering with industry, and identifying paths to market for badly-needed pediatric devices.鈥�

There are a variety of reasons to explain the lack of appropriately developed medical devices for children. In addition to design issues, there is a lack of standards for the development process, and a market size that doesn鈥檛 drive investment and create sufficient data to understand efficacy and support regulatory approval. The economic challenges mean that the return on the investment required to develop and test pediatric devices usually falls below the profit goals of medical device companies. 鈥淏y applying SRI鈥檚 proven methods for high-impact research together with early and ongoing involvement of pediatric clinicians, engineers, and a networked community dedicated to the successful transition of pediatric medical devices to the market, we聽 will address a critical need in pediatric medical care,鈥� said Pablo Garcia, an SRI principal engineer. 鈥淎lthough there are regulatory and economic challenges, we will work to overcome the barriers and develop medical devices intended specifically for the treatment of children.鈥�

The work of the MISTRAL pediatric device consortium will be performed by a cross-functional team聽 comprised of technical staff from SRI, physicians and medical staff from Stanford and Packard Children鈥檚, consultants, and industry professionals. To improve opportunities for the successful commercialization of pediatric devices, researchers will work closely with a distinguished group of advisors that will evaluate technologies and provide feedback on business plans. A venture-philanthropic program, the Pediatric Device Fund, will be established to support the development of products that do not have sufficient market pull, but that would provide significant clinical benefits if brought to the market.

鈥淭he Institute for Pediatric Innovation has pioneered a needs-driven innovation model to overcome the traditional barriers to pediatric device innovation,鈥� said Ross Trimby, chief operating officer at IPI. 鈥淲e have organized a national consortium of pediatric hospitals that partner with us in defining needs and setting priorities, establishing product feasibility, and in detailed design and development of pediatric devices. This process has resulted in industry agreements to develop three NICU devices using this process. We are pleased that this collaboration will enable us to partner with one of the nation鈥檚 leading engineering resources to address additional needs in neonatal care.鈥� The FDA-funded pediatric device consortium project will be led by MISTRAL co-founders Sanjeev Dutta and Pablo Garcia. Garcia leads research in medical systems and medical product development, telemedicine and robotic surgery. Dutta is a nationally recognized leader in minimal-access surgery and defined the area of stealth surgery, a 鈥渟carless鈥� approach to pediatric operations.

Authors

Robert Dicks
(650) 497-8364
rdicks@stanfordchildrens.org

About the Institute for Pediatric Innovation

The Institute for Pediatric Innovation (), a nonprofit organization, was formed to foster innovation to improve pediatric care by stimulating development of appropriate medical devices and drugs designed specifically for babies and children. Working with a Consortium of Pediatric Hospitals, IPI strives to identify the most needed products. IPI organizes public, private, nonprofit and for-profit collaborations in product innovation and licenses the resulting products to companies for commercial development. IPI is led by an experienced team of experts in licensing technology in pediatric medical care, commercializing medical technology, and marketing medical devices and pharmaceutical products. To date, IPI has received support from its consortium members along with the Ewing Marion Kauffman Foundation, Children's Medical Ventures, Inc., AGA Medical, Oxford Bioscience Partners and the World Health Organization (WHO).

About SRI International

Silicon Valley-based聽聽is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for聽more than 60 years. Perhaps best known for its invention of the聽computer mouse and interactive computing, SRI has also been responsible for major advances in聽networking and communications,聽robotics,聽drug discovery and development,聽advanced materials,聽atmospheric research,聽education research, economic development,聽national security, and more. The nonprofit institute performs聽sponsored research and development聽for聽government agencies,聽businesses, and聽foundations. SRI also聽licenses its technologies, forms聽strategic alliances, and creates聽spin-off companies. In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million. Sarnoff Corporation, a leader in vision, video, and semiconductor innovations, will be fully integrated into SRI effective January 1, 2011.